These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6905865)

  • 1. Application of good manufacturing practice regulations to investigational biologic products.
    Goebel PW
    J Parenter Drug Assoc; 1980; 34(5):348-51. PubMed ID: 6905865
    [No Abstract]   [Full Text] [Related]  

  • 2. Food and Drug Administration regulations and licensure.
    Barker LF
    Fed Proc; 1975 May; 34(6):1522-4. PubMed ID: 1126452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars legislation awakens data exclusivity debate.
    Hutson S
    Nat Med; 2009 Nov; 15(11):1242. PubMed ID: 19893548
    [No Abstract]   [Full Text] [Related]  

  • 5. Application of the Food and Drug Administration's current good manufacturing practices regulations to pharmacy practice: a legal view.
    Fink JL
    Contemp Pharm Pract; 1979; 2(4):202-5. PubMed ID: 10244540
    [No Abstract]   [Full Text] [Related]  

  • 6. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Food and Drug Administration and the backward motion toward the source.
    Kennedy D
    Public Health Rep; 1978; 93(6):607-15. PubMed ID: 362468
    [No Abstract]   [Full Text] [Related]  

  • 8. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supplements and other changes to an approved application. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Apr; 69(68):18727-67. PubMed ID: 15072041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. View from the Nation's Capital. New drug application (NDA) and investigational new drug (IND) regulations.
    Romansky MA
    J Clin Psychopharmacol; 1983 Dec; 3(6):380-3. PubMed ID: 6680409
    [No Abstract]   [Full Text] [Related]  

  • 11. Medical devices of human origin.
    Williams D
    Med Device Technol; 2001 Apr; 12(3):8, 10-1. PubMed ID: 11547687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of gene therapy products and the impact of manufacturing changes on product comparability.
    Simek SL
    Dev Biol (Basel); 2005; 122():139-44. PubMed ID: 16375258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foreign establishment registration and listing. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Nov; 66(228):59138-61. PubMed ID: 11776289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Environmental assessment requirements for live biological drugs.
    Sutton A
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S112-4; discussion S144-51. PubMed ID: 18181713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Conference on Harmonisation; guidance on Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Jun; 70(125):37861-2. PubMed ID: 15988855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological products; blood specificity designators; technical amendments--FDA. Final rule; technical amendments.
    Fed Regist; 1994 May; 59(87):23636-7. PubMed ID: 10184096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current good manufacturing practices.
    Zuck TF
    Transfusion; 1995; 35(11):955-66. PubMed ID: 8604495
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 20. Legal developments relevant to FDA authority.
    Meron D
    Food Drug Law J; 2007; 62(2):441-4. PubMed ID: 17632974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.